Lexicon Pharma (LXRX) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.48 +2.07%
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
SFBC, KSBI, PVBK, More
Revenue Growth %: -79.9%
Financial Fact:
Consolidated net loss per common share, basic and diluted: -0.35
Today's EPS Names:
SFBC, KSBI, PVBK, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $1.25 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
- Baker Hughes Company (BKR) Tops Q3 EPS by 10c
- Sound Finl Bancorp (SFBC) Tops Q3 EPS by 90c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
